Ignite Creation Date:
2024-05-05 @ 11:33 PM
Last Modification Date:
2024-10-26 @ 10:35 AM
Study NCT ID:
NCT01354808
Status:
COMPLETED
Last Update Posted:
2013-09-24
First Post:
2011-05-15
Brief Title:
ACCEL-LOADING-ACS Study
Sponsor:
Gyeongsang National University Hospital
Organization:
Gyeongsang National University Hospital
Study Overview
Official Title:
ACCELerated Inhibition of Platelet Aggregation Inflammation and Ischemia-reperfusion Injury by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome
Status:
COMPLETED
Status Verified Date:
2013-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether adjunctive cilostazol loadingmaintenance to standard treatment aspirin clopidogrel and statin is effective in reduction of major adverse cardiovascular events platelet activation inflammation and myonecrosis in patients with non-ST-elevation acute coronary syndrome ACSundergoing percutaneous coronary intervention PCI
Detailed Description:
In ACS patients platelet activation inflammation and ischemia-reperfusion injury can be closely associated with the risk of post-PCI myonecrosis and ischemic events occurrence In the ACCEL-AMI Adjunctive Cilostazol versus high maintenance-dose ClopidogrEL in patients with Acute Myocardial Infarctionstudy adjunctive cilostazol increased platelet inhibition compared with double-dose clopidogrel Meanwhile statins can reduce the extent of myonecrosis via limiting inflammation and myocardial infarct size by activating phosphatidylinositol-3-kinase PI3K ecto-5-nucleotidase Aktendothelial nitric oxide synthase eNOS and the downstream effectors inducible nitric oxide synthase iNOS and cyclooxygenase-2 COX-2 Inhibition of PI3K adenosine receptors eNOS iNOS or COX-2 abrogates the protective effects of statins In animal study the combination of low-dose statin with cilostazol synergistically limits infarct size Multiple studies have shown that cilostazol can influence inflammation and RISK pathway using the similar pathway with statin This study will be performed to evaluate the role of adjunctive cilostazol in platelet inhibition inflammation and myonecrosis compared with standard treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None